INS and cancer: Third, an ever-growing number of pre-clinical studies have proposed numerous cell-autonomous (e.g., AMPK/mTOR-related) and non-cell-autonomous (e.g., insulin/IGF-1-related) molecular mechanisms that have enthusiastically endorsed the clinical development of metformin as a novel anti-cancer drug (13–15).